Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsERON, Joseph J; COOPER, David A; LOUTFY, Mona R et al.Lancet. Infectious diseases (print). 2013, Vol 13, Num 7, pp 587-596, issn 1473-3099, 10 p.Article

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatmentSMITH, Kimberly Y; PATEL, Parul; WANNAMAKER, Paul et al.AIDS (London). 2009, Vol 23, Num 12, pp 1547-1556, issn 0269-9370, 10 p.Article

Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Highly active antiretroviral therapy decreases Mortality and morbidity in patients with advanced HIV diseaseMURPHY, Edward L; COLLIER, Ann C; KALISH, Leslie A et al.Annals of internal medicine. 2001, Vol 135, Num 1, pp 17-26, issn 0003-4819Article

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment- Experienced Patients with Drug- Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsSTEIGBIGEL, Roy T; COOPER, David A; YENI, Patrick et al.Clinical infectious diseases. 2010, Vol 50, Num 4, pp 605-612, issn 1058-4838, 8 p.Article

Determinants of antimicrobial prophylaxis use and treatment for wasting among patients with advanced human immunodeficiency virus disease in the United States, 1995-1998MURPHY, Edward L; ASSMANN, Susan F; COLLIER, Ann C et al.Clinical infectious diseases. 2001, Vol 32, Num 1, pp 116-123, issn 1058-4838Article

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsERON, Joseph J; YOUNG, Benjamin; KUMAR, Princy N et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 396-407, issn 0140-6736, 12 p.Article

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV infection who require transfusionsPARA, Michael F; KALISH, Leslie A; COLLIER, Ann C et al.Journal of acquired immune deficiency syndromes (1999). 2001, Vol 26, Num 4, pp 320-325, issn 1525-4135Article